Search Results - "Palmer, Cynthia L"

Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations by Johnson, Ted W, Richardson, Paul F, Bailey, Simon, Brooun, Alexei, Burke, Benjamin J, Collins, Michael R, Cui, J Jean, Deal, Judith G, Deng, Ya-Li, Dinh, Dac, Engstrom, Lars D, He, Mingying, Hoffman, Jacqui, Hoffman, Robert L, Huang, Qinhua, Kania, Robert S, Kath, John C, Lam, Hieu, Lam, Justine L, Le, Phuong T, Lingardo, Laura, Liu, Wei, McTigue, Michele, Palmer, Cynthia L, Sach, Neal W, Smeal, Tod, Smith, Graham L, Stewart, Albert E, Timofeevski, Sergei, Zhu, Huichun, Zhu, Jinjiang, Zou, Helen Y, Edwards, Martin P

“…Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-positive non-small-cell lung carcinoma patients, progression during…”
Get full text

Epithelial tissue hyperplasia induced by the RAF inhibitor PF-04880594 is attenuated by a clinically well-tolerated dose of the MEK inhibitor PD-0325901 by Torti, Vince R, Wojciechowicz, Donald, Hu, Wenyue, John-Baptiste, Annette, Evering, Winston, Troche, Gabriel, Marroquin, Lisa D, Smeal, Tod, Yamazaki, Shinji, Palmer, Cynthia L, Burns-Naas, Leigh Ann, Bagrodia, Shubha

“…Clinical trials of selective RAF inhibitors in patients with melanoma tumors harboring activated BRAFV600E have produced very promising results, and a RAF…”
Get full text

RUPTURE AND REBELLION: REIMAGINING THE OLDER WOMAN IN TWO SHORT STORIES BY ANGÉLICA GORODISCHER by Palmer, Cynthia L.

Get full text

2-Chloro-4-(1H-pyrazol-1-yl)-5-(trifluoro-meth-yl)pyrimidine by Bunker, Kevin D, Moore, Curtis, Palmer, Cynthia L, Rheingold, Arnold L, Yanovsky, Alex

“…The reaction of 2,4-dichloro-5-(trifluoro-meth-yl)pyrimidine with 1H-pyrazole gave two structural isomers in a 1:1 ratio that were separable by chromatography…”
Get full text

Voice-Overs: Translation and Latin American Literature by Palmer, Cynthia L.

Get full text

Escrituras de sobrevivencia: Narrativa argentina y dictadura by Palmer, Cynthia L.

Get full text

Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib by Huang, Qinhua, Johnson, Ted W, Bailey, Simon, Brooun, Alexei, Bunker, Kevin D, Burke, Benjamin J, Collins, Michael R, Cook, Andrew S, Cui, J. Jean, Dack, Kevin N, Deal, Judith G, Deng, Ya-Li, Dinh, Dac, Engstrom, Lars D, He, Mingying, Hoffman, Jacqui, Hoffman, Robert L, Johnson, Patrick S, Kania, Robert S, Lam, Hieu, Lam, Justine L, Le, Phuong T, Li, Qiuhua, Lingardo, Laura, Liu, Wei, Lu, Melissa West, McTigue, Michele, Palmer, Cynthia L, Richardson, Paul F, Sach, Neal W, Shen, Hong, Smeal, Tod, Smith, Graham L, Stewart, Albert E, Timofeevski, Sergei, Tsaparikos, Konstantinos, Wang, Hui, Zhu, Huichun, Zhu, Jinjiang, Zou, Helen Y, Edwards, Martin P

“…Crizotinib (1), an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration in 2011, is…”
Get full text

Structures of Power: Essays on Twentieth-Century Spanish-American Fiction by Palmer, Cynthia L.

Get full text

Abstract PR10: Is CNS availability for oncology a no-brainer? Discovery of PF-06463922, a novel small molecule inhibitor of ALK/ROS1 with preclinical brain availability and broad spectrum potency against ALK-resistant mutations by Johnson, Ted W., Bailey, Simon, Burke, Benjamin J., Collins, Michael R., Cui, J. Jean, Deal, Judy, Deng, Ya-Li, Edwards, Martin P., He, Mingying, Hoffman, Jacqui, Hoffman, Robert L., Huang, Qinhua, Kania, Robert S., Le, Phuong, McTigue, Michele, Palmer, Cynthia L., Richardson, Paul F., Sach, Neal W., Smith, Graham L., Engstrom, Lars, Hu, Wenyue, Lam, Hieu, Lam, Justine L., Smeal, Tod, Zou, Helen Y.

“…Abstract Oncogenic fusions of anaplastic lymphoma kinase (ALK) define a subset of human lung adenocarcinoma. The 1st generation ALK inhibitor crizotinib…”
Get full text

Discovery of (10R)‑7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H‑8,4-(metheno)pyrazolo­[4,3‑h]­[2,5,11]-benzoxa­diaza­cyclo­tetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations by Johnson, Ted W, Richardson, Paul F, Bailey, Simon, Brooun, Alexei, Burke, Benjamin J, Collins, Michael R, Cui, J. Jean, Deal, Judith G, Deng, Ya-Li, Dinh, Dac, Engstrom, Lars D, He, Mingying, Hoffman, Jacqui, Hoffman, Robert L, Huang, Qinhua, Kania, Robert S, Kath, John C, Lam, Hieu, Lam, Justine L, Le, Phuong T, Lingardo, Laura, Liu, Wei, McTigue, Michele, Palmer, Cynthia L, Sach, Neal W, Smeal, Tod, Smith, Graham L, Stewart, Albert E, Timofeevski, Sergei, Zhu, Huichun, Zhu, Jinjiang, Zou, Helen Y, Edwards, Martin P

“…Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-positive non-small-cell lung carcinoma patients, progression during…”
Get full text